DreaMed Diabetes has won CE Mark clearance for its Advisor Pro decision-support platform, designed to help healthcare professionals manage insulin therapy for their Type I diabetes patients. The company’s cloud-based platform provides personalized insulin treatment plans by combining data from insulin pumps and continuous glucose monitors. Using machine learning techniques, the system analyzes all of […]
Diabetes
Sanofi touts real-world data for Toujeo insulin glargine injection
Sanofi (NYSE:SNY) touted data today from its 10,000-patient Lightning study, which evaluated electronic medical records of adults with Type II diabetes to study its long-acting insulin glargine injection, Toujeo. The company found that Toujeo significantly lowered patients’ risk of experiencing severe low blood sugar compared to other long-acting insulin, like its own Lantus product. The data, […]
Tandem closes $69m underwritten public offering
Tandem Diabetes Care (NSDQ:TNDM) has closed its previously-announced underwritten public offering of 30 million shares of common stock at $2.00 apiece. The San Diego, Calif.-based company reeled in $69 million from the offering, after underwriters exercised an option to buy 4.5 million additional shares of Tandem’s common stock. The insulin pump-maker has tried to drum up […]
Glooko wins FDA nod for mobile insulin dosing system
The FDA has approved Glooko‘s mobile insulin dosing system, which is designed to titrate long-acting insulin for people with Type II diabetes. The company’s system accesses blood glucose data directly from the user’s glucose meter so that the user doesn’t have to manually enter their fasting glucose values. Then, it analyzes those levels to recommend […]
Insulet’s closed-loop insulin delivery algorithm succeeds in feasibility study
The algorithm used in Insulet‘s (NSDQ:PODD) closed-loop insulin delivery system performed well in a 58-patient safety and feasibility study, according to a study published today in Diabetes Technology & Therapeutics. Insulet’s device, which is still in development, combines an insulin dosing algorithm, the OmniPod insulin patch pump and Dexcom‘s (NSDQ:DXCM) continuous glucose monitor into one system […]
Diabetes clinic taps DarioHealth for blood glucose monitoring tech
DarioHealth (NSDQ:DRIO) has partnered with the Diabetes and Endocrinology Consultants of Pennsylvania to bring its blood glucose monitoring system to the 5,000-patient facility. The company’s blood glucose monitor, which syncs with Dario’s diabetes management app, connects via a headphone jack to a mobile device, helping diabetes patients monitor their blood glucose throughout the day. The app also […]
Insulet settles investor suit for $20m
Insulet (NSDQ:PODD) plans to fork over $19.5 million to settle a class action lawsuit brought by the Arkansas Teacher Retirement System, the City of Bristol Pension Fund and the City of Omaha Police and Fire Retirement System, according to court documents. The lawsuit alleged that Insulet misrepresented the success of its OmniPod Eros roll-out in 2013, which eventually […]
DarioHealth inks deal to use blood glucose tech in pharma company’s clinical trial
DarioHealth (NSDQ:DRIO) said today that it inked a deal with an unnamed pharmaceutical company to combine its blood glucose monitoring tech into the company’s clinical trial. The Israel-based device-maker reported that this pharmaceutical company is conducting a trial of its diabetes drug that will eventually be included in a regulatory package for FDA approval. DarioHealth has […]
Congress doles out $300m to fund diabetes research
Congress today approved a two-year extension of the Special Diabetes Program, giving the National Institutes of Health $300 million to fund research into new therapies and technologies for people with Type I diabetes. The program, which has historically garnered bipartisan support, was last reauthorized in 2015 when lawmakers budgeted $150 million over two years for […]
Tandem Diabetes Care prices $60m offering
Tandem Diabetes Care (NSDQ:TNDM) has priced an underwritten public offering of 30 million shares of common stock at $2.00 apiece. The San Diego, Calif.-based company said it expects to reel in $60 million from the offering. Tandem also gave underwriters a 30-day option to buy up to 4.5 million more shares of common stock. The offering […]